Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Sixers coach Doc Rivers encouraged Matisse Thybulle to get vaccinated but continued ‘to support the kid’

PHILADELPHIA — Doc Rivers has known all season that 76ers starting wing Matisse Thybulle was not vaccinated against COVID-19. Rivers added he “encouraged [Thybulle] all year” to receive the required shot(s).

The Philadelphia Inquirer

What's Going On With Myovant Sciences Stock Today?

Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New Drug Application for MYFEMBREE for the manag

Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

COVID vaccines: why second boosters are being offered to vulnerable people in the UK – but not young and healthy people yet

Until recently, the UK government limited a fourth dose of the COVID vaccine to people with severely weakened immune systems over the age of 16.

The Conversation

Pfizer offers $100m to buy Brisbane company behind smartphone app that diagnoses COVID-19

Pfizer offers $100 million to buy a ResApp, a company that has invented a smartphone app it says can diagnose COVID-19 by listening to someone cough.

ABC News

Matisse Thybulle Not Fully Vaccinated, Can’t Play in Toronto for First Round of Playoffs

Matisse Thybulle has only gotten one shot of the Pfizer vaccine and won’t be able to play in some of Philadelphia’s first-round games.

Sports Illustrated

Explained | Why India administers ‘precaution dose’ of COVID-19 vaccine, and not ‘booster dose’

As India gears up to administer ‘precaution doses’ of COVID-19 vaccine to eligible population above 18 years from Sunday, the debate over ‘booster’ vs ‘precaution’ doses has arisen.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

China's Health System Faces Raft of Challenges as Omicron Hits

China is battling its biggest spike in coronavirus cases since the start of the pandemic, with millions under lockdown and the healthcare system feeling the pressure. One of the last countries sticking to a zero-Covid strategy, China aims to stamp out every infection with strict lockdowns and by sending all…

Asharq Al-Awsat

Looking At Pfizer's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 47 strange trades.

Benzinga

Michael Hiltzik: The anti-vaxxers' campaign against public health advocates gets scarier and more rabid

Last December, we reported on the threatening behavior of a group of anti-vaccine activists toward Kristina Lawson, the president of the Medical Board of California.

Los Angeles Times

TGA approves Pfizer COVID-19 boosters for 12-15-year-olds, final approval needed from ATAGI

The Therapeutic Goods Administration has approved the Pfizer COVID booster for people aged 12 to 15, but it will need a final tick of approval before it is made available to the cohort.

ABC News

Egypt Receives 1.5 Million COVID Vaccine Doses from US

Egypt has received 1.5 million doses of Pfizer’s coronavirus vaccine donated by the US government. Acting Health Minister Khaled Abdel Ghaffar said Egypt received 1,501,110 Pfizer COVID-19 vaccine doses gifted by the US and delivered through the COVAX initiative and in cooperation with the Vaccine Alliance (GAVI). The new batch…

Asharq Al-Awsat

What's Going On With Pfizer Stock Today?

Pfizer Inc (NYSE: PFE) shares are trading higher Thursday. The company announced the acquisition of ReViral for a total consideration of up to $525 million.

Benzinga

What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?

Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer Beefs Up Its RSV Antiviral Portfolio With $525M ReViral Acquisition

Pfizer Inc (NYSE: PFE)

Benzinga

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Axios

The high-stakes push to get COVID vaccines to young children

The Omicron variant and and anti-vaccine backlash are complicating the effort.

Tribune News Service

Second COVID booster shot extends protection for just a few weeks, study shows

A fourth shot of the Pfizer COVID-19 vaccine increased protection against viral infection for only four to seven weeks, according to a massive study published Tuesday.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Sadiq Khan calls on leading vaccine manufacturers to share Covid jab blueprints with world

Exclusive: Sadiq Khan, alongside mayors of New York and Johannesburg, urged companies ‘to do all you can’ to promote vaccine equity and ‘help stop the unnecessary loss of life’

Benzinga

Pfizer/BioNTech's Second COVID-19 Vaccine Booster Provides Short-Lived Protection In Elderly, Israel Study Shows

An Israel-based study has found that a fourth dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) vaccine lowered rates of COVID-19 infection among the elderly.

Asharq Al-Awsat

No Evidence to Support Widespread Use of Fourth COVID Shot, Say EU Agencies

EU health agencies said on Wednesday there was no evidence to support the use of a fourth dose of COVID-19 vaccines developed by Pfizer and Moderna in the general population, but they recommend a second booster for people aged 80 and above. There is no clear evidence in the European…

Daily Mirror

New Covid antibody rates, how vaccine works, immunity – and how long you’re protected for

As Covid infection rates remain high across the country and people continue to lose their lives, we take a look at how the vaccines work, antibody levels across the UK and how quickly protection drops off

Reuters

Second booster shields elderly from COVID but protection wanes quickly - study

A fourth dose of the Pfizer/BioNTech vaccine lowered rates of COVID-19 among the elderly but the protection against infection appeared short-lived, a large study in Israel has found.

Tribune News Service

Future of COVID boosters comes down to crucial meeting of FDA Advisers

An all-star panel of COVID-19 experts will convene this week to hash out how and when vaccines should be updated to address future variants as the virus continues to rapidly mutate.

Benzinga

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

1 … 57 58 59 60

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.